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The vascular disease involves imbalanced function of the blood vessels. Risk factors playing a role in development of impaired
vessel functions will be briefly discussed. In ischemia/reperfusion (I/R), ischemic hypoxia is one of the cardinal risk factors of
restenosis. Various insults are shown to initiate the phenotype switch of VSMCs. The pathological process, leading to activated
inflammatory process, complement activation, and release of growth factors, initiate the proliferation of VSMCs in the media and
cause luminal narrowing and impaired vascular function. The review summarizes the alteration process and demonstrates some
of the clinical genetic background showing the role of complement and the genotypes of mannose-binding lectin (MBL2). Those
could be useful markers of carotid restenosis after stent implantation. Gene therapy and therapeutic angiogenesis is proposed for
therapy in restenosis. We suggest a drug candidate (iroxanadine), which ensures a noninvasive treatment by reverse regulation of
the highly proliferating VSMCs and the disturbed function of ECs.
1. Introduction
A luminal narrowing in the arterial vessel wall is induced
by injury that is leading to stenosis and development of
intimal hyperplasia [1]. The balloon coronary angioplasty
has represented a revolutionary treatment that led to the
birth of interventional cardiology. This new special surgery
process with the exclusion surgical intervention produces
ischemia reperfusion, inflammation and final to restenosis
with an occlusion of arterial lumen. Proven indications for
endarterectomy as recoil are moderate-to-high grade steno-
sis, rapidly progressive stenosis with lesions revealing greater
than 70 percent in diameter of stenosis in carotid diseases.
Clinical results reveal primary success rates, less compli-
cation, and restenosis rates comparable with those of surgical
endarterectomy. The coronary stents, which were first devel-
oped in the mid-1980s, have ultimately replaced the “old
balloon angioplasty” as the preferred method of performing
percutaneous transluminal coronary angiography (PTCA)
intervention [2]. After the observed improvements (in
angiographic and clinical outcomes), this field represents the
most common major worldwide medical procedure. Several
groups have been published the similar results like as our
group. 171 interventions on 151 patients were performed
as a single surgeon’s experiences and long-term follow-up
was completed in 109 patients. The combined survival rate
was 85%, recurrent stenosis-free 88% at 5 years, respectively.
Only 9% of the patients had carotid restenosis >70% [3].
Reduction of the incidence of clinical events was only
possible if a low perioperative complication rate was accom-
plished. Nowadays involve a coronary stent, and interven-
tional cardiologists are faced with a wide choice of coronary
stents to implant, such as bare metal stents and drug-eluting
stents. Coronary stenting only became a widely accepted
technique [4]. In spite of some relevant strong points such
as greater than 90% success rate and the repeatability of the
procedure, several major drawbacks still persist, including
restenosis within the treated vessel [5–8]. The restenosis
phenomenon is currently the object of intensive research in
diﬀerent areas of biomedical field and therapy.
Restenosis means the reoccurrence of stenosis, a narrow-
ing of a blood vessel, leading to restricted blood flow. Res-
tenosis usually sets to an artery or other large blood vessel
that has become narrowed. This phenomenon is grown up
after balloon intervention with an enhanced inflammatory
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processes and the blood vessel subsequently becomes renar-
rowed. This term is common in vascular surgery, cardiac
surgery, and angioplasty, all branches of medicine that
frequently treat narrowing of blood vessels [9]. Restenosis
can be defined as a reduction in the circumference of the
lumen of 50% or more and had a high incidence rate (25–
50%) in patients who had undergone balloon angioplasty,
with the majority of patients needing further angioplasty
within 6 months [10].
Damage to the blood vessel wall by angioplasty triggers
physiological response that occurs immediately after tissue
trauma, is thrombosis. A blood clot forms at the site of
damage and further hinders blood flow with an inflamma-
tory response. The second stage tends to occur 3–6 months
after surgery and is the result of proliferation of cells in
the intima, a smooth muscle wall in the vessel. This is also
known as early restenosis, namely, neointimal hyperplasia
[11]. The artery can react to the stent, perceive it as a foreign
body, and respond by mounting an immune system response
(see physiology below) which leads to further narrowing
near to or inside the stent. Drug-eluted stents substantially
reduce the occurrence of restenosis clinical studies indicate
a slight incidence rate of recurrence (≥5% ) [12]. Obviously
restenosis remains a problem.
Restenosis is mainly due to neointima formation, which
is caused primarily by the eﬀects of VSMC proliferation and
migration [12]. Cell proliferation after stenting occurs both
early, as part of the acute injury response, and late, located
around stent struts. Whereas some neointima formation is
necessary for vessel healing after stenting, excessive neoin-
tima formation narrows the lumen [13]. The function of
endothelium plays a central role in destroyed balance and
later the maintaining of vascular health by virtue of the
endothelial cells [14]. Leakage of the endothelium lining
and prolonged endothelial proliferation is characterized
after the intervention [15]. Development of restenosis has
demonstrated high proliferation activity of VSMC from the
tunica media to the intima which is the occurrence of
internal elastic lamina rupture [16, 17]. To summarize, the
adverse cardiovascular events are associated to endothelial
dysfunction and activated proliferation of VSMC [18].
Atherosclerosis is coexistence with occlusion of arterial
wall and the etiology of the disease distinct of restenosis. It
is known as vascular disease in which an artery wall thickens
as a result of the accumulation of cholesterol. It is a chronic
inflammatory response, caused largely by the accumulation
ofmacrophages and lymphocytes and promoted by high level
of oxidized low-density lipoproteins [19]. It is commonly
referred to as a hardening of the arteries and caused by
the formation of multiple plaques within the arteries. The
advanced atherosclerosis is chronic, slowly progressive, and
cumulative process. Most commonly, the soft plaques sud-
denly create ruptures [20] causing the formation of a throm-
bus and incidentally leading to death of the tissues (infarc-
tion).
The most important risk factors of MIH and restenosis
are ischemia/reperfusion injury, shear stress, inflammation,
diabetes, oxidative stress, hypertension, modulation of cyto-
kine, and C-reactive protein [CRP] level, together with other
environmental stimuli such as smoking. Those factors which
appear to have impact on the evaluation of restenosis will be
briefly mentioned in this review.
1.1. Ischemia/Reperfusion (I/R) Injury. I/R injury plays a
significant role in the pathophysiology of restenosis by
inducing endothelial dysfunction. Ischemia induces rapid
and gradual injuries in cells of blood vessels. The arterial
blood vessel is vulnerable to I/R injury which depends on
the ischemic time, hemodynamic status of patients, and
the reperfusion itself. I/R injury of endothelial cells (ECs)
apparently provide an initial trigger and subsequently causes
enhanced proliferation of VSMCs. Thus, diminution of I/R
injury would be a great benefit not only by inhibiting direct
cellular injury but also indirectly through the mentioned
factors that influence several processes, for example, the
immune response [21]. The injury can block the artery or
result in poor perfusion of reperfused tissue of blood vessel.
PTCA causes a significant inflammatory response compared
to angiography alone. Ischemia/reperfusion injury correlated
with restenosis and inflammatory response. Time-dependent
increased level of IL-6 and TNF-alpha has detected in PTCA
patients [22].
1.2. Shear Stress. Vascular homeostasis on arterial walls is
highly dependent on the blood flow and shear stress. Re-
sponses to shear stresses (laminal and oscillatory) are well
summarized [23]. Endothelial cells act as sensors of shear
stress and regulate its level by adapting the arterial dimen-
sions to blood flow. Shear stresses control and modify
function of cells in arterial wall. In the presence of several
risk factors, low shear stress contributes to endothelial dys-
function, whereas normal-to-high shear stress results in
protecting the function of blood vessel. High shear stress
upregulates the expression of endothelial genes and proteins
which are protected against dysfunction, and by low shear
stress an opposite eﬀect is produced. The role of shear stress
in restenosis is less understood [23]. Disturbed flow has been
proven to result in postsurgical neointimal hyperplasia, in-
stent stenosis, and aortic valve calcification [24].
1.3. Immune Factors. The immune system plays important
roles in restenosis. Endothelial injury and activation elicits
the release of proinflammatory cytokines, chemokines, and
expression of adhesion molecules, which fosters immune cell
recruitment and transmigration of immune cells across the
EC barrier and into the intima. The role of various immune
components in restenosis is complex. The current review
will not delve into details regarding the role of immunity in
development of restenosis [25–27].
1.4. Thromboembolism. Thromboembolism, governed by
several risk factors (hypertension, diabetes, obesity, smoking,
etc.) constitutes an increased risk and complication of hos-
pitalization. The phenomena of thromboembolism overlap
with the phenomena of atherothrombosis and/or restenosis
[28].
1.5. Elevated Serum C-Reactive Protein Level. Elevated C-re-
active protein (CRP) level associated with inflammation may
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promote the restenosis process. Exogenous CRP induces
the expression of adhesion molecules [29] and decreases
endothelial NOS (eNOS) production [30]. Furthermore,
CRP upregulates SMC angiotensin-I receptors and thereby
increases the level of the reactive oxygen species as well as
proliferation [31]. In addition, monocytes/macrophages ex-
posed to CRP increase the release of tissue factor, which
potentially stimulates cell migration and adhesion to endo-
thelial cells [32] extending inflammatory process and finally
results in restenosis.
1.6. Hyperhomocysteinemia. Epidemiological evidence shows
that high level of serum homocysteine is associated with
an increased risk of cardiovascular diseases. Hyperhom-
ocysteinemia aﬀects primarily the endothelium, which in
turn results in reduced endothelial NO production, de-
creased arterial response to vasodilators, and increased ex-
pression of procoagulant factors. Normalization of serum
homocystein level might be an eﬀective therapeutic approach
[33].
1.7. Further Risk Factors. Among others, hypertension,
smoking, and diabetes mellitus are risk factors associated to
the development of restenosis. Hypertension causes endothe-
lial injury by promoting the formation of intimal hyperplasia
[2]. In spite of our increasing knowledge on the nature and
eﬀect of numerous risk factors, partially covered above, fur-
ther studies are clearly needed to establish important features
of their mode of action as well as their interactions in the
pathogenesis of myointimal hyperplasia and restenosis. We
suggest that I/R injury and hypoxia are one of the initiative
risk factors of restenosis, acting by disturbing the normal
functioning of the endothelial monolayer. As a result, en-
dothelial cells release enhanced levels of inflammatory cy-
tokines and growth factors, leading to phenotype switch
of the vascular smooth muscle cells, followed by their in-
creased migration and/or proliferation. This suggestion will
be further developed below.
2. Cellular and Physiological Events
during Restenosis
2.1. Endothelial Cells. The endothelium regulates many im-
portant functions in the cardiovascular system including vas-
cular tone, coagulation, and inflammatory responses. In ad-
dition, the endothelium limits local thrombosis by produc-
ing tissue plasminogen activator, maintaining a negative-
ly charged surface, and secreting heparans, NO, and throm-
bomodulin [34].
NO, a paracrine factor produced by the endothelial NO
synthase enzyme (eNOS) is well known as vasodilator [35].
In addition, its eﬀect is crucial for several other processes
as well, involving the prevention of platelet aggregation/ad-
hesion and reduction of the expression of several proinflam-
matory genes. Pharmacological inhibition or genetic defi-
ciency of eNOS hampers endothelium-dependent vasodila-
tation, impairs tissue blood flow, and raises the blood
pressure [36].
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Figure 1: Correlation of phenotype, mechanical and functional
plasticity of VSMCs (figure from [41]).
NO plays a key role in maintaining vascular homeostasis,
by exerting a wide variety of eﬀects on the endothelial and
smooth muscle cells of the vessel wall. It stimulates endo-
thelial cell proliferation, mainly by potentiating the mito-
genic eﬀect of vascular endothelial growth factor. On the
contrary, in the case of VMSCs, NO inhibits their prolifera-
tion andmigration. As a consequence, enhancedNOproduc-
tion in the vessel wall slows down or even reverses restenosis
[37, 38].
Beside NO, mitogens (e.g., PDGF) produced by ECs are
also important regulators of VSMCs. Selective inhibition of
PDGF production by low-density lipoprotein has potentially
profound implications for the clinical control of MIH [39].
In summary, endothelial dysfunction (mechanical injury
to the endothelium) is an important early feature of vascular
injury with serious impact on the pathogenesis of restenosis.
2.2. Vascular Smooth Muscle Cells and Phenotype Switch.
Induced proliferation of VSMCs contributes to the pathobi-
ology of restenosis and linked also to other cellular processes
such as inflammation, apoptosis, and matrix alterations. In
fact, beside inflammation enhanced proliferation of VSMCs
is one of the key processes of restenosis and atherosclerosis
[40].
Enhanced proliferation of VSMCs is most probably the
consequence of phenotype switch of these cells. Phenotype
switch is a complex cellular mechanism providing the pos-
sibility of adult smooth muscle cells to fluctuate reversibly
between a contractile and an “immature” (also called “pro-
liferative”) phenotype. In response to various inner and envi-
ronmental signals, these two phenotypes exert diﬀerent
activities: contractile smoothmuscle cells stiﬀen, shorten and
relax, whereas the immature ones have a tendency to prolif-
erate, to migrate, and to synthesize extracellular matrix com-
ponents. It is to be noted, that within both phenotypes func-
tional diversity occurs, that is, distinct populations might
coexist which respond diﬀerently to given stimuli [41]. This
is schematized in Figure 1.
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Molecular mechanisms underlying the functional plas-
ticity of the contractile phenotype are centered on (a) remod-
eling of the actomyosin filaments constituting the contractile
apparatus [42], and (b) variation of the expression of pro-
teins regulating cell responses to environmental cues. Nu-
merous proteins belong to this latter group, involving re-
ceptors, signaling eﬀectors, ion channels, and so forth, pre-
ferentially sequestered in caveolae, flask-shaped invagina-
tions of the plasma membrane. Caveolae are of primary im-
portance in regulating the phenotype switch of VSMCs [43].
Caveolae components are diﬀerently organized in the distinct
myocyte phenotypes; they are more abundant in contractile
vascular myocytes [44]. In contractile VSMCs they regulate
processes leading to functional plasticity, and they are sug-
gested to be involved the integration of events leading to
phenotype switch.
At least two transmembrane adhesion receptors, the in-
tegrins and the dystrophin-glycoprotein complex (DGC) are
present in caveolae, which constitute a link between the ex-
tracellular matrix (ECM) components, (e.g., laminins) and
the intracellular actin filament system, being therefore key
players in the communication of the cells with their envi-
ronment. Noticeably, diﬀerent types of integrins and DGC
components are expressed in VSMCs of diﬀerent phenotypes
(for a review, cf. [45]).
In the course of restenosis, one of the first steps of the
lesion development is the focal accumulation of VSMCs
within the intima. The local inflammatory milieu can induce
expression of collagenase and inhibit expression of prote-
olytic inhibitors [46]. In advanced lesions, fibroblasts and
VSMCs with extracellular calcification form a fibrocalcific
plaque. The origin of VSMCs in the atherosclerotic plaque
is controversial. The VSMC population in intimal lesions has
been proposed to arise from medial VSMCs [47], adventitial
cells [48], preexisting intimal clones [49], and precursor cells
derived from the vessel wall itself or from circulating vascular
progenitors [50]. Several factors have been found to aﬀect
VSMCs. Principal factors among these are platelet-derived
growth factor (PDGF), somatomedin-C, epithelial growth
factor, and insulin. Lipoproteins may be also important
substrates for VSMC proliferation, while heparin directly
inhibits VSMC protein synthesis [51, 52]. Internal lesion
of arterial wall EC results in subsequent proliferation of
VSMCs. The degree of VSMC proliferation appears to be
dependent mainly on the degree of initial injury and par-
tially, but not in all cases on loss the confluence of overlying
endothelium. Heparin and other EC products appear to
inhibit VSMC proliferation independently of platelet-VSMC
interaction. Platelets may play a role in the early response to
arterial injury and development of MIH, but their long-term
role appears to be minor [52, 53]. Hypertension results in
a marked proliferation of VSMC enhancing the proliferative
response to injury.
Structural organization and signaling of VSMCs and
thereby phenotype switch are influenced by externally
applied mechanical force as well. The predominant mechan-
ical force acting this way is cyclic stretch, which regulates the
activity of their contractile apparatus. Drug therapy directed
at the components of the signaling pathways influenced by
stretch may prevent myointimal hyperplasia and thereby
restenosis [54].
Recently, we have discovered that hypoxia; one of the car-
dinal risk factors of restenosis influences both the endothelial
monolayer and the VSMCs. These cell types are inverse
regulated by a single short duration of hypoxia. Endothelial
cells undergo apoptosis, whereas the proliferative activity of
VSMCs increases significantly [55]. The contractile pheno-
type of VSMCs is changed to proliferative type.
3. Clinical Features of the Restenosis
3.1. Clinical Analysis and Diagnostic Markers. In the last
decades surgery techniques have been routinely performed
[2, 56]. The restenosis is one of the most common and dan-
gerous postoperative complication of these interventions.
Pathology of coronary diseases in general comprises several
distinct features involving, among others, degenerative and
cell proliferation/diﬀerentiation processes. Cell proliferation
and diﬀerentiation disturb the cellular morphogenesis [57]
leading to the formation of a multilayered compartment
internally to the elastic membrane of the arterial wall, com-
posed of cells expressing alpha-smooth-muscle actin [58].
This process is termed as “arterial intimal hyperplasia” “my-
ointimal hyperplasia,” or “neointima formation,” and it is the
leading pathological mechanism leading to the narrowing of
the arterial lumen. Arterial intimal hyperplasia is one of the
main factors of coronary artery diseases [59]. It is destructive
event of the postoperative complications after angioplasty,
bypass operations, or stenting as well [60, 61]. Several at-
tempts have been made to interfere with the development
of postoperative intimal hyperplasia, of which application of
drug-eluting stents (DES) seems to be the most promising
approach [57, 62].
Our vascular surgeon team has been performing endo-
vascular interventions since decades. In a comprehensive
retrospective study [3, 61], it was shown that the 5-year
patient survival rate after carotid endarterectomy (CEA) was
85%, and the restenosis-free rate among the survivors was
88%.
Physiological and pathophysiological factors leading to
restenosis were studied. Changes in the levels of two acute
phase proteins, plasma fibrinogen, and serum C-reactive
protein (s-CRP) were determined in 117 patients with severe
carotid stenosis after eversion endarterectomy [63]. During
the postoperative period sharp, highly significant drop oc-
curred in the serum concentrations of both acute phase
proteins. These findings indicate that the removal of athero-
sclerotic plaques from the carotid arteries markedly decreases
the production of the two acute phase proteins. This
phenomenon is due to the decrease of the inflammatory
burden.
3.2. Role of Mannose-Binding Lectin and Complement on
Restenosis. The role of mannose-binding lectin (MBL2) gen-
otype in restenosis after eversion endarterectomy in pa-
tients with severe carotid atherosclerosis has been also stud-
ied [64]. MBL is thought to influence the pathophysiology
of the cardiovascular system by decreasing the risk of
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advanced atherosclerosis and by contributing to enhanced
ischemia reperfusion injury. Our data show that carotid du-
plex scan (CDS) values in patients homozygous for the nor-
mal (A) MBL2 genotype were significantly higher 14 months
postsurgery as compared to the values measured 6 weeks
after surgery. On the other hand, only a slight increase was re-
gistered in patients carrying variant MBL2 alleles. The
frequency of MBL2 variant genotype was significantly higher
in patient’s not experiencing restenosis as compared with pa-
tients with restenosis. These results indicate that reoccur-
rence of stenosis after carotid endarterectomy is influenced
by genetic factors and imply that MBL2 contributes to the
pathophysiology of this condition.
In our previous study, we analyzed the relationship of C3
complement component with early restenosis, detected by
CDS, after eversion endarterectomy by analysing three non-
complement acute-phase reactants (APRs) (C-reactive pro-
tein, haptoglobin, and alpha2-HS glycoprotein/fetuin-A)
as control [65]. In MBL2 A/A allele carriers C3 levels in-
creased during the follow-up period and correlated with
the occurrence of restenosis at 14 months postsurgery. Even
after adjusting for MBL2 genotype, age and gender, patients
with high C3 levels had nearly five-fold higher odds for the
development of significant restenosis (>50% reduction in
diameter) By contrast, no such associations were detected be-
tween early restenosis and the noncomplement APRs. C3 is
thus associated with the development of an early restenosis
after eversion endarterectomy, which is related to an intact
MBL lectin pathway. These results suggest that C3 levels
probably have clinical importance and indicate that the
regulation of C3 diﬀers from noncomplement APRs.
Several growth factors are also suggested to contribute
to restenosis. We investigated whether early postoperative
changes in serum vascular endothelial growth factor (VEGF)
and platelet-derived growth factor (PDGF) concentrations
are in correlation with the MBL2 genotype in the context
of the development of restenosis [66]. The data indicated
that pronounced significant increases in both VEGF and
PDGF-predicted restenosis exclusively in patients who were
homozygous for the normal MBL2 genotype. In this group,
the adjusted odds ratio of restenosis at 14 months was
27.7 (2.4 to 317.2) in patients with high early VEGF and
PDGF increases, while in patients with low early growth
factor increases the odds ratio was 9.2 (1.4 to 58.7). These
findings indicate that in patients disposed to restenosis by
MBL2 genotype pathologic processes leading to enhanced
production of VEGF and PDGF during the very early
postoperative period exert more harmful eﬀect as compared
to patients with the “protective” MBL2 genotype [66].
Considering the impact of MBL2 genotype on the occur-
rence of early restenosis after CEA, the role of C1-inhibitor
(C1-INH), known as an inhibitor of the lectin pathway, has
been also studied [67]. The aim of the study was to de-
termine whether the C1-INH levels have predictive value
for restenosis after CEA. Patients with >50% restenosis had
significantly lower C1-INH levels at 6 weeks and at 4 days
postsurgery. C1-INH levels at 6 weeks correlated inversely
with the CDS values at 14 months (r = −0.3415), but only
in MBL2 A/A homozygotes (r = −0.5044). Patients with
low C1-INH levels had higher CDS values already at 7
months postsurgery. Patients with MBL2 A/A and low C1-
INH levels at 6 weeks postsurgery had 13.9 times higher risk
developing an early restenosis. These data indicate thatMBL2
genotyping together with measuring the C1-INH level at 6
weeks postsurgery should be useful for identifying patients
with high risk for early carotid restenosis.
4. Therapy
Pharmacological treatments currently in use include anti-
coagulants, antiplatelet agents, immunosuppressants, and
antiproliferation agents. Unfortunately, none of these ap-
proaches has been conclusively shown to prevent coronary
restenosis after balloon angioplasty or graft restenosis after
peripheral arterial bypass. Consequently, the treatment of
vascular stenosis remains today predominantly within the
domain of the surgery. However, numerous successful animal
experiments and promising proposals, as well as initial
clinical results have been published lately. Here we review
some remarkable contributions to this field.
4.1. Preclinical Investigations. As unfolded earlier, hypoxia is
one of the risk factors which initiate the pathological mech-
anism leading to restenosis. The obvious target cells of
restenosis therapy are the permanent proliferating VSMCs
and the endothelial cells with injured function. The possi-
bility of influencing the process of the phenotype switch of
VSMCs to proliferative form during pathological, ischemic
conditions would open up new vistas in the prevention
and/or therapy of restenosis. Techniques addressing directly
the proliferating VSMCs or injured endothelial cells have
demonstrated significant degrees of clinical success.
A recent review has summarizied the present status of
cellular and animal studies aimed at preventing restenosis
by using protein kinase C (PKC) inhibitors. These agents
are expected to exert therapeutically beneficial eﬀects on
restenosis causing factors of various kinds, including VSMCs
[68].
Angiogenesis, that is, the growth of new blood vessels
from existing host vessels, is recognized more and more as
an important factor in the growth and progression of reste-
nosis. Neovascularization as a pathological process was al-
ready known in the 19th century. The phenomenon occurs
when the intima thickens beyond the diﬀusion limits of
oxygen and nutrients, as a response to tissue hypoxia and
consists of growth and extension of adventitial blood vessels
into the intima [69]. Under hypoxic conditions the hypoxia-
inducible factor alpha is upregulated and promotes hypoxia-
dependent neovascularization. Blood vessels are destabilized,
and this leads ultimately to vessel regression. In the pres-
ence of vascular endothelial growth factor (VEGF), Ang2
facilitates vascular sprouting with enhanced migration and
proliferation of ECs. A high Ang2/Ang1 ratio has been found
in vulnerable neovascularized plaques [70]. Other molecules
and growth factors (VEGF and FGF) have also been shown
to induce neovascularization and thereby increase nutrient
perfusion. Treatment with these agents was named ther-
apeutic angiogenesis by Freedman and Isner [71]. VEGF
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has therapeutic potential in cardiovascular gene therapy,
the enhancement of arterioprotective endothelial functions,
prevention postangioplasty restenosis. VEGF promotes the
cell growth and survival, regeneration of endothelial cells.
Whereas the production of NO in endothelial cells is induced
by VEGF, the proliferation of vascular smooth muscle cell
is inhibited. Inhibition of neointimal hyperplasia may also
be achieved by gene transfer of endothelial NO synthase
(eNOS), PGI synthase, or cell-cycle regulators cyclin-de-
pendent kinase inhibitors, p53, and transcription factors
such as nuclear factor kappaB [72]. The opposite eﬀects are
resulted by VEGF-inhibited angiogenesis in oncology.
It has been suggested that bone marrow-derived endo-
thelial progenitor cells (EPCs) or circulating endothelial pro-
genitor cells play a role in neovascularization [73, 74]. Never-
theless, it is not yet clear whether these progenitor cells
should be considered as therapeutic targets in vascular dis-
eases [75].
Iroxanadine (5,6-dihydro-5-(1-piperidinyl)methyl-3-(3-
pyridil)-4H-1,2,4-oxadiazine) is a drug candidate with a
marked cytoprotection by heat shock protein (HSP) coin-
duction. It has been originally synthesized by Biorex-Hun-
gary (BRX-235) [76], and the worldwide rights have been
recently sold by CytRx/California/USA to Orphazyme ApS/
Novo A/S, Copenhagen, Denmark. In a recent work we have
shown that BRX-235 stimulates the migration of ECs via p38
stress-activated-protein-kinase (SAPK) and enhanced ex-
pression of HSPs and heat-shock transcription factors [77].
After treatment by BRX-235, the vigorous proliferation of
MIH cells decreased while the proliferation of deregulated
EC cells increased. Simultaneously, the expression of both
HSP72 and Cdkn1a was upregulated. This finding harmo-
nizes with a clinical report demostrating compromised EC
proliferation, and HSP72 expression was upregulated in
VSMCs [78]. Neointima formation due to enhanced VMSC
proliferation is suggested to be associated with reduced cyclic
guanosine monophosphate signaling. We have undertaken
to study the eﬀect of the inhibition of cyclic guanosine
monophosphate degradation on neointima formation in a
rat model of endarterectomy, by using the selective phos-
phodiesterase-5 inhibitor vardenafil as a pharmacologi-
cal inhibitor. The results were evaluated by conventional
microscopy with hematoxylin and eosin staining and by im-
munohistochemical analysis to confirm neointima forma-
tion and the local cyclic guanosine monophosphate content
[79]. Immunohistochemical analysis demonstrated intensive
staining for transforming growth factor beta1 (TGF beta1)
and alpha-smooth muscle actin in the control neointima.
Vardenafil significantly reduced the stenosis grade (24.64%
versus 54.12% in the control group) and expression of TGF
beta1, as well as alpha-smoothmuscle actin in the neointima.
On the basis of these results it was suggested to consider
the treatment with vardenafil as a new possibility to prevent
neointimal hyperplasia after endarterectomy.
4.2. Clinical Observations. Stent insertion, one of the most
common surgical techniques applied in vascular diseases,
is too often followed by early, as well as late restenosis. To
attenuate this complication, instead of conventional stents,
drug-eluting stents (DESs) are more and more frequently
applied [80].
Stents generally attenuate endothelial recovery, altering
thereby the natural biology of the vessel wall and increasing
the associated risk of stent thrombosis [81]. DESs, similarly
to brachytherapy, target proliferating VSMCs at the site of
injury and have been successful in reducing the forma-
tion of neointimal lesion [80–82]. DESs releasing various
antiproliferative drugs represent also a useful strategy for
the prevention of restenosis. VEGF-2 gene-eluting stents
accelerate reendothelization, thereby oﬀering an alternative
strategy for the prevention of restenosis. This type of treat-
ment, when applied in hypercholesterolemic rabbits, resulted
in transgene expression in the vessel wall and a 2.4-fold
increase in NO production by the ECs, along with improved
functional recovery of stented segments [82].
The DES technique significantly decreases the incidence
of restenosis. Follow-up studies, however, show the possible
onset of late stent thrombosis [81]. Delayed arterial healing
most probably associated with poor endothelialization of
stent struts seems to be the underlying mechanism of this
complication [83]. As recent results indicate, balloon angio-
plasty and stent implantation might still go hand in hand
with severe postoperative complications. Several drugs have
been suggests to use in DES, for example, antitumor agents
(paclitaxel, doxorubicine, rapamycin, erythromycin, etc.),
cholesterin lowering drugs (statins), immunosuppressants
(cyclosporin), anti-inflammatory agents (Rapamycin), anti-
biotics (amphotericin B), and natural products (shikonin).
Rapamycin is considered to be extremely useful in preventing
restenosis [84].
4.3. Gene Therapy. Finally, we briefly summarize the achieve-
ments of gene therapy, as an emerging approach to coun-
teract the pathological processes leading to restenosis. None
of the gene therapy agents have been approved for clinical
use up to now, but several promising animal experiments
and preclinical studies have been recently published. The
great potential advantage of the gene therapy resides in its
potential to ensure specific, controlled expression of selected
proteins within the targeted cell types. The panoply of gene
therapy possibilities, among others the potential of promot-
ing a functional epithelium, inhibiting SMC proliferation
and therapeutic angiogenesis has been summarized in a
review [85]. Several approaches of gene transfer have been
designed for the treatment of postangioplasty restenosis.
Adenoviruses (Ads) and adeno-associated viruses (AAVs) are
currently the most eﬃcient vectors for delivering therapeutic
genes into the vascular system [86, 87]. Gene therapy is often
associated with the drug-eluting stent (DES) technique; that
is, the therapeutic gene is delivered by the stent [85, 87].
Along this line, local delivery of NOS gene seems to be
the most promising approach. On the basis of successful
animal application of iNOS gene transfer, a single-blind,
multicenter clinical study has been recently performed by
iNOS lipoplex gene therapy [88]. The results suggest that the
technique applied provide a safe therapeutic principle for the
prevention of coronary restenosis. Consequently, the authors
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suggest further clinical research to develop this promising
possibility.
5. Conclusion
As a conclusion, we predict that significant clinical benefits
are to be expected when using complex therapeutically ap-
proaches, which stimulate physical and functional recovery
of the endothelial monolayer and in the same time inhibit
the proliferation of vascular smooth muscle cells.
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